Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease

Current Medicinal Chemistry

Volumn 18, Issue 5, 2011, Pages 714-724

  Marin M ^a   Manez S ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Asymmetric dimethylarginine; Cardiovascular diseases; Nitric oxide; Protein post translational modifications

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6 N,N' DIMETHYLARGININE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALKALOID DERIVATIVE; AMINO ACID; ANGIOTENSIN II ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FARNESOID X RECEPTOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HOMOCYSTEINE; HORMONE RECEPTOR STIMULATING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELATONIN; METHYLTRANSFERASE; N(G),N(G) DIMETHYLARGININE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENOL; ROSIGLITAZONE; RUTAECARPINE; SAPONIN DERIVATIVE; TELMISARTAN; ZOFENOPRIL;

ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE MARKER; DRUG STRUCTURE; ENTERITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; METHYLATION; MICROCIRCULATION; NONHUMAN; PROTEIN PROCESSING; VASCULAR DISEASE;

ADRENERGIC ANTAGONISTS; ANGIOTENSINS; ARGININE; DIABETES COMPLICATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY DISEASES; MICROCIRCULATION; NITRIC OXIDE SYNTHASE TYPE III; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASCULAR DISEASES;

EID: 79951547424     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794480087     Document Type: Article

References (76)

1. McBride, A. E.; Silver, P. A. State of the Arg: Protein methylation at arginine comes of age. Cell, 2001, 106, 5-8. (Pubitemid 32709951)
2. Bedford, M. T.; Clarke, S. G. Protein arginine methylation in mammals: Who, what, and why. Mol. Cell, 2009, 33, 1-13.
3. Teerlink, T.; Luo, Z.; Palm, F.; Wilcox, C. S. Cellular ADMA: Regulation and action. Pharmacol. Res., 2009, 60, 448-460.
4. Pahlich, S.; Zakaryan, R. P.; Gehring, H. Protein arginine methylation: Cellular functions and methods of analysis. Biochim. Biophys. Acta., 2006, 1764, 1890-1903. (Pubitemid 44895022)
5. Closs, E. I.; Gräf, P.; Habermeier, A.; Cunningham, J. M.; Förstermann, U. Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: three related carriers with distinct transport properties. Biochemistry, 1997, 36, 6462-6468. (Pubitemid 27231404)
6. Nakamura, T.; Sato, E.; Fujiwara, N.; Kawagoe, Y.; Suzuki, T.; Ueda, Y.; Yamada, S.; Shoji, H.; Takeuchi, M.; Ueda, S.; Matsui, T.; Adachi, H.; Okuda, S.; Yamagishi, S. Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol. Res., 2009, 60, 15-18.
7. Sud, N.; Wells, S. M.; Sharma, S.; Wiseman, D. A.; Wilham, J.; Black, S. M. Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction. Am. J. Physiol. Cell Physiol., 2008, 294 C, 1407-1418.
8. Fiedler, L. R.; Bachetti, T.; Leiper, J.; Zachary, I.; Chen, L.; Renné, T.; Wojciak-Stothard, B. The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 2117-2124.
9. Wells, S. M.; Buford, M. C.; Migliaccio, C. T.; Holian, A. Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice. Am. J. Respir. Cell. Mol. Biol., 2009, 40, 179-188.
10. Leiper, J.; Murray-Rust, J.; McDonald, N.; Vallance, P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc. Natl. Acad. Sci. USA, 2002, 99, 13527-13532. (Pubitemid 35215415)
11. Chen, M.; Li, Y.; Yang, T.; Wang, Y.; Bai, Y.; Xie, X. ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells. Cytokine, 2008, 43, 149-159.
12. Maron, B. A.; Loscalzo, J. The treatment of hyperhomocysteinemia. Annu. Rev. Med., 2009, 60, 39-54.
13. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 2002, 288, 2015-2022.
14. Austin, R. C.; Lentz, S. R.; Werstuck, G. H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ., 2004, 11, S56-S64. (Pubitemid 39136799)
15. Stühlinger, M. C.; Tsao, P. S.; Her, J. H.; Kimoto, M.; Balint, R. F.; Cooke, J. P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation, 2001, 104, 2569-2575. (Pubitemid 33104795)
16. Rodionov, R. N.; Dayoub, H.; Lynch, C. M.; Wilson, K. M.; Stevens, J. W.; Murry, D. J.; Kimoto, M.; Arning, E.; Bottiglieri, T.; Cooke, J. P.; Baumbach, G. L.; Faraci, F. M.; Lentz, S. R. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ. Res., 2010, 106, 551-558.
17. Nishikawa, T.; Araki, E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid. Redox Signal., 2007, 9, 343-353. (Pubitemid 46150966)
18. Lin, K. Y.; Ito, A.; Asagami, T.; Tsao, P. S.; Adimoolam, S.; Kimoto, M.; Tsuji, H.; Reaven, G. M.; Cooke, J. P. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002, 106, 987-992. (Pubitemid 34925335)
19. Chobanyan, K.; Thum, T.; Suchy, M. T.; Zhu, B.; Mitschke, A.; Gutzki, F. M.; Beckmann, B.; Stichtenoth, D. O.; Tsikas, D. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 858, 32-41. (Pubitemid 47513589)
20. Lu, C. W.; Guo. Z.; Feng, M.; Wu, Z. Z.; He, Z. M.; Xiong, Y. Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells. Atherosclerosis, 2010, 209, 66-73.
21. Böger, R. H.; Bode-Böger, S. M.; Szuba, A.; Tsao, P. S.; Chan, J. R.; Tangphao, O.; Blaschke, T. F.; Cooke, J. P. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998, 98, 1842-1847. (Pubitemid 28509278)
22. Bode-Böger, S. M.; Böger, R. H.; Kienke, S.; Junker, W.; Frölich, J. C. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem. Biophys. Res. Commun., 1996, 219, 598-603.
23. Böger, R. H.; Bode-Böger, S. M.; Brandes, R. P.; Phivthong-ngam, L.; Böhme, M.; Nafe, R.; Mügge, A.; Frölich, J. C. Dietary L-arginine reduces the progression of atherosclerosis in cholesterolfed rabbits: comparison with lovastatin. Circulation, 1997, 96, 1282-1290. (Pubitemid 27344234)
24. Böger, R. H.; Bode-Böger, S. M.; Thiele, W.; Junker, W.; Alexander, K.; Frölich, J. C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation, 1997, 95, 2068-2074. (Pubitemid 27184275)
25. Kraml, P.; Syrovátka, P.; Stipek, S.; Fialová, L.; Koprivová, H.; Potocková, J.; Andel, M. Hyperlipoproteinemia impairs endothelium-dependent vasodilation. Physiol. Res., 2004, 53, 471-480. (Pubitemid 39486703)
26. Böger RH. Asymmetric dimethylarginine (ADMA) modulates endothelial function-therapeutic implications. Vasc. Med., 2003, 8, 149-151. (Pubitemid 38220191)
27. Ito, A.; Tsao, P. S.; Adimoolam, S.; Kimoto, M.; Ogawa, T.; Cooke, J. P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation, 1999, 99, 3092-3095. (Pubitemid 29289071)
28. Böger, R. H.; Sydow, K.; Borlak, J.; Thum, T.; Lenzen, H.; Schubert, B.; Tsikas, D.; Bode-Böger, S. M. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res., 2000, 87, 99-105. (Pubitemid 30616904)
29. Päivä, H.; Laakso, J.; Ruokonen, I.; Luomala, M.; Saarela, M.; Solakivi, T.; Metso, S.; Nikkilä, M.; Wuolijoki, E.; Laaksonen, R.; Lehtimäki, T. Plasma asymmetric dimethylarginine (ADMA), nitrate and the indices of low-density lipoprotein oxidation. Clin. Chim. Acta, 2006, 371, 97-101. (Pubitemid 44162900)
30. Shah SV. The role of reactive oxygen metabolites in glomerular disease. Annu. Rev. Physiol, 1995, 57, 245-262.
31. Sharma, M.; McCarthy, E. T.; Savin, V. J.; Lianos, E. A. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int., 2005, 68, 2735-2744. (Pubitemid 43251018)
32. + ATPase. Acta Biochim. Pol, 2004, 51, 933-942. (Pubitemid 40187565)
33. Cazevieille, C.; Muller, A.; Meynier, F.; Bonne, C. Superoxide and nitric oxide cooperation in hypoxia/reoxygenation-induced neuron injury. Free Radic. Biol. Med., 1993, 14, 389-395. (Pubitemid 23087402)
34. Katusic, Z. S. Superoxide anion and endothelial regulation of arterial tone. Free Radic. Biol. Med, 1996, 20, 443-448. (Pubitemid 26077867)
35. McCarty, M. F. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med. Hypotheses, 2004, 63, 699-708. (Pubitemid 39485844)
36. Toth, J.; Racz, A.; Kaminski, P. M.; Wolin, M. S.; Bagi, Z.; Koller, A. Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone. Hypertension, 2007, 49, 563-568.
37. Osanai, T.; Saitoh, M.; Sasaki, S.; Tomita, H.; Matsunaga, T.; Okumura, K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension, 2003, 42, 985-990. (Pubitemid 37413742)
38. Sasser, J. M.; Moningka, N. C.; Cunningham, M. W. Jr.; Croker, B.; Baylis, C. Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol, 2010, 298, R740-R746.
39. Beltowski, J.; Kedra, A. Asymmetric dimethylarginine (ADMA) as a target pharmacotherapy. Pharmacol. Rep., 2006, 58, 159-178.
40. Young, J. M.; Strey, C. H.; George, P. M.; Florkowski, C. M.; Sies, C. W.; Frampton, C.; Scott, R. S. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with nonischaemic heart failure. Eur. J. Heart Fail., 2008, 10, 463-466.
41. Nanayakkara, P. W.; Kiefte-de Jong, J. C.; ter Wee, P. M.; Stehouwer, C. D., van Ittersum, F. J.; Olthof, M. R.; Teerlink, T.; Twisk, J. W.; van Guldener, C.; Smulders, Y. M. Randomized placebocontrolled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am. J. Kidney Dis., 2009, 53, 41-50.
42. Ivashchenko, C. Y.; Bradley, B. T.; Ao, Z.; Leiper, J.; Vallance, P.; Johns, D. G. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and-2. Am. J. Physiol. Heart Circ. Physiol., 2010, 298, H251-H258.
43. Ilerigelen, B.; Uresin, Y.; San, M.; Kültürsay, H.; Güneri, S.; Serdar, O. A.; Güleç, S.; Pençedemir, H. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). Curr. Med. Res. Opin., 2007, 23, 1093-1102. (Pubitemid 46799593)
44. Nakamura, T.; Sato, E.; Fujiwara, N.; Kawagoe, Y.; Ueda, Y.; Suzuki, T.; Ueda, S.; Adachi, H.; Okuda, S.; Yamagishi, S. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol. Res., 2009, 60, 525-528.
45. Yang, T. L.; Chen, M. F.; Xia X.; Luo, B. L.; Li, Y. J. Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. Eur. J. Clin. Pharmacol., 2006, 62, 179-184. (Pubitemid 43357575)
46. Dierkes, J.; Westphal, S.; Martens-Lobenhoffer, J.; Luley, C.; Bode-Böger, S. M. Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. Atherosclerosis, 2004, 173, 239-244. (Pubitemid 38469791)
47. Stühlinger, M. C.; Abbasi, F.; Chu, J. W.; Lamendola, C.; McLaughlin, T. L.; Cooke, J. P.; Reaven, G. M.; Tsao, P. S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002, 287, 1420-1426. (Pubitemid 34250505)
48. Richir, M. C.; Ellger, B.; Teerlink, T.; Siroen, M. P.; Visser. M.; Spreeuwenberg, M.; Girbes, A. R.; van der Hoven, B.; van den Berghe, G.; Wilhelm, A. J.; de Vries, T. P.; van Leeuwen, P. A. The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients. Pharmacol. Res., 2009, 60, 519-524.
49. Wakino, S.; Hayashi, K.; Tatematsu, S.; Hasegawa, K.; Takamatsu, I.; Kanda, T.; Homma, K.; Yoshioka, K.; Sugano, N.; Saruta, T. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens. Res., 2005, 28, 255-262. (Pubitemid 40812611)
50. Celik, T.; Iyisoy, A.; Yuksel, C.; Jata, B. The beneficial effects of angiotensin-converting enzyme inhibitors on serum asymmetric dimethylarginine levels in the patients with cardiovascular disease. Int. J. Cardiol., 2010, 142, 107-109.
51. Aslam, S.; Santha, T.; Leone, A.; Wilcox, C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int., 2006, 70, 2109-2115. (Pubitemid 44871373)
52. Chen, J. W.; Hsu, N. W.; Wu, T. C.; Lin, S. J.; Chang, M. S. Longterm angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol., 2002, 90, 974-982.
53. Delles, C.; Schneider, M. P.; John, S.; Gekle, M.; Schmieder, R. E. Angiotensin converting enzyme inhibition and angiotensin II AT1 receptor blockade reduce the levels of asymmetrical N (G), N (G) - dimethylarginine in human essential hypertension. Am. J. Hypertens., 2002, 15, 590-593. (Pubitemid 34734805)
54. Benson, S. C.; Pershadsingh, H. A.; Ho, C. I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery, M. A.; Kurtz, T. W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004, 43, 993-1002. (Pubitemid 38579904)
55. Ono, Y.; Nakaya, Y.; Bando, S.; Soeki, T.; Ito, S.; Sata, M. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Int. Heart J., 2009, 50, 73-83.
56. Chen, M. F.; Xie, X. M.; Yang, T. L.; Wang, Y. J.; Zhang, X. H.; Luo, B. L.; Li, Y. J. Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J. Vasc. Res., 2007, 44, 391-402.
57. Chen, M. F.; Li, Y. J.; Yang, T. L.; Lou, B.; Xie, X. M. Losartan inhibits monocytic adhesion induced by ADMA via downregulation of chemokine receptors in monocytes. Eur. J. Clin. Pharmacol., 2009, 65, 457-464.
58. Napoli, C.; Sica, V.; de Nigris, F.; Pignalosa, O.; Condorelli, M.; Ignarro, L. J.; Liguori, A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J., 2004, 148, e5.
59. Alfieri, A. B.; Briceno, L.; Fragasso, G.; Spoladore, R.; Palloshi, A.; Bassanelli, G.; Montano, C.; Arioli, F.; Cuko, A.; Ruotolo, G.; Margonato, A. Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. J. Cardiovasc. Pharmacol., 2008, 52, 49-54.
60. Garbin, U.; Pasini, A. F.; Stranieri, C.; Manfro, S.; Boccioletti, V.; Cominacini, L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol. Res., 2007, 56, 515-521. (Pubitemid 350137774)
61. Pasini, A. F.; Garbin, U.; Stranieri, C.; Boccioletti, V.; Mozzini, C.; Manfro, S.; Pasini, A.; Cominacini, M.; Cominacini, L. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am. J. Hypertens., 2008, 21, 1251-1257.
62. Hu, T.; Chouinard, M.; Cox, A. L.; Sipes, P.; Marcelo, M.; Ficorilli, J.; Li, S.; Gao, H.; Ryan, T. P.; Michael, M. D.; Michael, L. F. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J. Biol. Chem., 2006, 281, 39831-39838. (Pubitemid 46041786)
63. Li, J.; Wilson, A.; Gao, X.; Kuruba, R.; Liu, Y.; Poloyac, S.; Pitt, B.; Xie, W.; Li, S. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X Receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine. J. Pharmacol. Exp. Ther., 2009, 331, 234-243.
64. Monsalve, E.; Oviedo, P. J.; García-Pérez, M. A.; Tarín, J. J.; Cano, A.; Hermenegildo, C. Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovasc. Res., 2007, 73, 66-72. (Pubitemid 44937184)
65. Tooke, J. E.; Shore, A. C.; Cohen, R. A.; Kluft, C. Diabetic angiopathy: Tracking down the culprits. J. Diabetes Complications, 1996, 10, 173-181. (Pubitemid 26235763)
66. Ozgurtas, T., Oktenli, C.; Dede, M.; Tapan, S.; Kenar, L.; Sanisoglu, S. Y.; Yesilova, Z.; Yenen M. C.; Erbil, M. K.; Baser, I. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis, 2008, 200, 336-344.
67. Charitidou, C.; Farmakiotis, D.; Zournatzi, V.; Pidonia, I.; Pegiou, T.; Karamanis, N.; Hatzistilianou, M.; Katsikis, I.; Panidis, D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis, 2008, 196, 958-965.
68. Tain, Y. L.; Hsieh, C. S.; Chen, C. C.; Sheen, J. M.; Lee, C. T.; Huang, L. T. Melatonin prevents increased asymmetric dimethylarginine in young rats with bile duct ligation. J. Pineal Res., 2010, 48, 212-221.
69. Liu, Y. Z.; Zhou, Y.; Li, D.; Wang, L.; Hu, G. Y.; Peng, J.; Li, Y. J. Reduction of asymmetric dimethylarginine in the protective effects of rutaecarpine on gastric mucosal injury. Can. J. Physiol. Pharmacol., 2008, 86, 675-681
70. Zhang, G. G.; Bai, Y. P.; Chen, M. F.; Shi, R. Z.; Jiang, D. J.; Fu, Q. M.; Tan, G. S.; Li, Y. J. Asymmetric dimethylarginine induces TNF-alpha production via ROS/NF-kappaB dependent pathway in human monocytic cells and the inhibitory effect of reinioside C. Vascul. Pharmacol., 2008, 48, 115-121.
71. Tang, W. J.; Hu, C. P.; Chen, M. F.; Deng, P. Y.; Li, Y. J. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level. Can. J. Physiol. Pharmacol., 2006, 84, 163-171.
72. Scalera, F.; Fulge, B.; Martens-Lobenhoffer, J.; Heimburg, A.; Bode-Böger, S. M. Red wine decreases asymmetric dimethylarginine via SIRT1 induction in human endothelial cells. Biochem. Biophys. Res. Commun., 2009, 390, 703-709.
73. Yuan, Q.; Peng, J.; Liu, S. Y.; Wang, C. J.; Xiang, D. X.; Xiong, X. M.; Hu, C. P.; Li, Y. J. Inhibitory effect of resveratrol derivative BTM-0512 on high glucose-induced cell senescence involves dimethylaminohydrolase/asymmetric dimethylarginine pathway. Clin. Exp. Pharmacol. Physiol., 2010, 37, 630-635.
74. Xiao, H. B.; Lu, X. Y.; Li, Y. J.; Xu, J. P.; Sun, Z. L. Effect of 3, 4, 5, 6-tetrahydroxyxanthone on erythrocyte deformability in apolipoprotein E-deficient mice. J. Asian Nat. Prod. Res., 2009, 11, 643-651.
75. Xiao, H. B.; Jun-Fang; Lu, X. Y.; Chen, X. J.; Chao-Tan; Sun, Z. L. Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level. Eur. J. Pharmacol., 2009, 616, 213-222.
76. Olmos, A.; Giner, R. M.; Recio, M. C.; Ríos, J. L.; Gil-Benso, R.; Máñez, S. Interaction of dicaffeoylquinic derivatives with peroxynitrite and other reactive nitrogen species. Arch. Biochem. Biophys., 2008, 475, 66-71.